Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013 (mitazalimab)
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Tumor-directed immunotherapy of cancer

Latest News

  • 23 Jun 2020 – Alligator Bioscience receives first patent approval for ATOR-1017
  • 15 Jun 2020 – Alligator Bioscience appoints new CFO
  • 10 Jun 2020 – Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
  • 4 Jun 2020 – Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
More news

Calendar

  • 13 Jul 2020 ‐ Interim report April-June 2020
  • 2 Sep 2020 — 3 Sep 2020 ‐ Pareto Securities’ 11th Annual Healthcare Conference
  • 10 Sep 2020 ‐ Redeye Investor Forum (virtual)

ATOR-1015 at ASCO 2020

ATOR-1015 poster presentation at ASCO Annual Meeting Virtual May 29-31, 2020. Read the poster here.

 

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree